Adequate hemostasis remains an important issue in
|
|
- Eustace Shields
- 5 years ago
- Views:
Transcription
1 Fresh Frozen Plasma in the Pediatric Pump Prime: A Prospective, Randomized Trial Mary M. McCall, MSN, Mindy M. Blackwell, MS, Jonathan T. Smyre, MS, Joseph J. Sistino, MPA, Jeffrey R. Acsell, BS, B. Hugh Dorman, MD, PhD, and Scott M. Bradley, MD Cardiovascular Perfusion Program, Department of Anesthesia, and Division of Cardiothoracic Surgery, Medical University of South Carolina, Charleston, South Carolina Background. The aim of this study was to determine whether the use of fresh frozen plasma (FFP) in the infant pump prime can avoid dilution of fibrinogen, decrease the need for blood product transfusion after bypass, and decrease exposure to donor blood products. Methods. Twenty infants weighing less than 8 kg were prospectively randomized to receive either 1UofFFP(10 patients) or no FFP (10 patients) in the pump prime. Mean age ( months), weight ( kg), total prime volume ( ml), cardiopulmonary bypass time, cross-clamp time, lowest temperature on bypass, and preoperative coagulation parameters did not differ between the two groups. Results. At the end of bypass, the mean fibrinogen level was significantly higher in the FFP than the no FFP group ( versus mg/dl; p < ), whereas the mean platelet count did not differ (60 25 versus K/mm 3 ; p 0.5). Patients in the FFP group received significantly fewer units of cryoprecipitate ( versus U/patient; p < 0.001), and had a mean total donor exposure of U/patient versus U/patient in the no FFP group (p 0.06). The mean chest tube output over the first 24 hours did not differ between groups. Conclusions. The use of FFP in the pump prime significantly limited dilutional hypofibrinogenemia, decreased the transfusion of cryoprecipitate after bypass, and tended to decrease the overall mean patient exposure to blood products. (Ann Thorac Surg 2004;77:983 7) 2004 by The Society of Thoracic Surgeons Adequate hemostasis remains an important issue in infants who have undergone cardiopulmonary bypass [1 3]. Compared with older patients, neonates and infants are at increased risk for impaired hemostasis, bleeding, and transfusion requirements after open-heart surgery [4, 5]. Patients weighing less than 8 kg have also been found to have increased rates of bleeding and blood product transfusion after cardiopulmonary bypass [6]. A major factor affecting the coagulation system during infant cardiopulmonary bypass is hemodilution. The proportionally large volume of the bypass pump prime compared with the patient s blood volume results in a significant decrease in platelet count and dilution of coagulation factors including fibrinogen [2, 6, 7]. The fibrinogen level at the end of bypass has, in turn, been shown to correlate with 24-hour chest tube drainage in children weighing less than 8 kg [6]. One approach to coagulation management in children undergoing cardiopulmonary bypass is the use of fresh whole blood [3]. However fresh whole blood is not readily available in all institutions. An alternative is the use of fresh frozen plasma (FFP) in the pump prime. We Presented at the Forty-ninth Annual Meeting of the Southern Thoracic Surgical Association, Miami Beach, FL, Nov 7 9, Address reprint requests to Dr Bradley, Division of Cardiothoracic Surgery, Medical University of South Carolina, 96 Jonathan Lucas St, Charleston, SC 29425; bradlesm@musc.edu. hypothesized that FFP might avoid dilution of coagulation factors, such as fibrinogen, and, in turn, decrease transfusion requirements. The aim of this study was to determine the effects of including FFP in the pump prime on fibrinogen levels and transfusion requirements in infants undergoing cardiopulmonary bypass. Material and Methods This study was approved by the Institutional Review Board of the Medical University of South Carolina. Informed consent was obtained from the parents or guardians of each patient. Twenty patients scheduled to undergo heart surgery were prospectively enrolled in the study. Inclusion criteria were a primary operation (nonreoperation) using cardiopulmonary bypass and weight less than 8 kg. Exclusion criteria included a preexisting coagulopathy documented either by history or an abnormal prothrombin time, partial thromboplastin time, or platelet count. Patients receiving a medication known to alter coagulation (such as aspirin) were also excluded. On the day before surgery, each patient was randomized, using a series of sealed envelopes, to receive either1uof FFP or no FFP in the cardiopulmonary bypass pump prime. No study patient received whole blood or any antifibrinolytic agent including aprotinin. Aprotinin has been shown to reduce bleeding in complex operations 2004 by The Society of Thoracic Surgeons /04/$30.00 Published by Elsevier Inc doi: /j.athoracsur
2 984 MCCALL ET AL Ann Thorac Surg FRESH FROZEN PLASMA IN THE PEDIATRIC PUMP PRIME 2004;77:983 7 Table 1. Bypass Pump Prime Constituents Total volume (ml) Packed red blood cells (ml) FFP (ml) a 25% Albumin (ml) a such as the arterial switch procedure [8]. As it is our policy, as well as that of others [9, 10] to administer aprotinin to all patients undergoing a Norwood or arterial switch procedure, none were included in this study. Operative Management The cardiopulmonary pump prime included Plasmalyte A (Baxter Healthcare Corp, Deerfield, IL), and packed red blood cells to achieve a postdilutional patient hematocrit roughly equal to the target cooling temperature (Table 1). One unit of FFP was added to the pump prime of the patients randomized to the FFP group. Additionally, 25% salt poor albumin (ZL:B Bioplasma AG, Bern, Switzerland) was added to achieve a colloid osmotic pressure of 16 mm Hg for each patient. Due to the colloid osmotic pressure of FFP the patients in the FFP group received less albumin in the prime than those in the no FFP group (Table 1). Prime medications included: heparin ( U), sodium bicarbonate (to achieve a ph of ), mannitol (250 mg/kg), cefazolin (25 mg/kg), and regitine (0.25 mg/kg) for a target cooling temperature less than 25 C. Anesthesia was induced and maintained with intravenous midazolam and fentanyl. Pancuronium was utilized for muscle relaxation. Systemic heparinization was achieved with a heparin dose of 400 U/kg. Activated clotting time (ACT) was measured every twenty minutes with a Hemochron 6000 system (International Technidyne Corp, Edison, NJ). All patients underwent ultrafiltration during bypass, as well as arteriovenous modified ultrafiltration immediately after bypass. Modified ultrafiltration was carried out to filter a volume equal to the prime volume, which generally took a period of 12 minutes. The protamine dose was calculated based on 60% of the total heparin given. Heparin reversal was verified by return of ACT to base line ten minutes after protamine administration. Study Protocol Laboratory tests (fibrinogen level, platelet count, prothrombin time, partial thromboplastin time, hematocrit) were determined before skin incision. The fibrinogen level and platelet count were repeated during the rewarming phase of bypass. After protamine administration blood products were administered according to a predetermined protocol: platelets (0.5 U/kg) were given for a platelet count less than 60 K/mm 3, and cryoprecipitate (0.5 U/kg) for a fibrinogen level less than 80 mg/dl. Table 2. Demographics and Operative Data Patients Cyanotic 3 2 Age (months) Weight (kg) Cardiopulmonary bypass time (min) Cross-clamp time (min) Lowest temperature ( C) Operation 0.6 Ventricular septal defect 2 5 Tetralogy of Fallot 3 1 TAPVR 3 0 Left atrial aneurysm 1 0 Secundum ASD 1 0 Cor triatriatum 0 1 Partial AVSD 0 1 Division main PA, 0 1 modified BT shunt Bidirectional Glenn shunt 0 1 ASD atrial septal defect; AVSD atrioventricular septal defect; BSA body surface area; BT Blalock-Taussig; FFP fresh frozen plasma; PA pulmonary artery; TAPVR total anomalous pulmonary venous return. If bleeding continued subsequently, laboratory tests were repeated and additional blood products administered at the discretion of the surgeon and anesthesiologist. These additional blood products were platelets (1 patient in each group), cryoprecipitate (2 patients in the FFP group), and FFP (3 patients in the no FFP group). Upon arrival in the intensive care unit, laboratory tests were repeated. The volume of chest tube output over the first 24 hours in the intensive care unit and the units of blood products administered in the operating room and over the first 24 hours in the intensive care unit were recorded. Statistics Data from the FFP and no FFP groups were compared by the unpaired Student t test, the Fischer exact test, or 2 test, as appropriate. Data are shown as mean SD. Statistical significance was defined as p Results Patients There was no significant difference in the age or weight of the patients in the FFP and no FFP groups (Table 2). Three patients in the FFP group and 2 patients in the no FFP group were cyanotic (baseline systemic oxygen saturation 90%) before operation. The mean cardiopulmonary bypass time, cross-clamp time, and lowest temperature on bypass did not differ between the two groups (Table 2). The operative procedures in the two groups are detailed in Table 2.
3 Ann Thorac Surg MCCALL ET AL 2004;77:983 7 FRESH FROZEN PLASMA IN THE PEDIATRIC PUMP PRIME Table 3. Laboratory Tests Preoperative Fibrinogen (mg/dl) Platelet count (K/mm 3 ) Prothrombin time (s) Partial thromboplastin time (s) Hematocrit (%) End of bypass Fibrinogen (mg/dl) a Platelet count (K/mm 3 ) ICU admission Fibrinogen (mg/dl) Platelet count (K/mm 3 ) Prothrombin time (s) Partial thromboplastin time (s) Hematocrit (%) Coagulation Parameters and Bleeding The preoperative mean fibrinogen level, platelet count, prothrombin time, and partial thromboplastin time did not differ between the FFP and no FFP patients (Table 3). However before the end of bypass, the mean fibrinogen level in the no FFP group had fallen to 58 mg/dl, whereas the mean fibrinogen level in the FFP group was significantly higher, 123 mg/dl (Table 3). The mean platelet count was low in both groups, 60 K/mm 3 in the FFP patients versus 52 K/mm 3 in the no FFP patients which was not a significant difference (Table 3). By the time of admission to the intensive care unit, there were again no differences between the two groups in mean fibrinogen level, platelet count, prothrombin time, or partial thromboplastin time (Table 3). The mean chest tube output over the first 24 hours in the intensive care unit was 10 7 ml/kg in the FFP group versus 10 5 ml/kg in the no FFP group (p 0.9). Donor Exposures The FFP and no FFP groups had a similar mean number of donor exposures from packed red blood cells (1.8 versus 2.1 U/patient) and from platelets (0.9 versus 1.0 U/patient; Table 4). As expected donor exposures from FFP were higher in the FFP group but this was offset by a Table 4. Donor Exposures Per Patient Packed red blood cells Platelets FFP a Cryoprecipitate a Total significantly lower number of donor exposures from cryoprecipitate (0.4 versus 2.0 U/patient; Table 4). Overall, the patients in the FFP group had a mean total donor exposure of 4.1 U/patient compared with 5.4 U/patient in the no FFP group (Table 4). This difference approached statistical significance (p 0.06). Comment 985 This study examined the effects of including FFP in the cardiopulmonary bypass pump prime of patients weighing less than 8 kg. We found that the use of FFP led to a significantly higher fibrinogen level at the end of bypass. This, in turn, led to less transfusion of cryoprecipitate and a trend toward less overall exposure to donor blood products. A major factor affecting the coagulation system in an infant undergoing cardiopulmonary bypass is the dilution of plasma proteins and platelets that results from the relatively large priming volume of the bypass pump [1, 11, 12]. Whereas an average-size adult s blood volume is diluted 25% 35% during cardiopulmonary bypass, dilution may be % in a neonate [11 13]. As a result, factor levels and platelet counts decrease markedly as soon as the patient is placed on bypass. Kern and associates observed that coagulation factors decreased 50% and platelet counts decreased 70% in neonates within 1 minute of being placed on bypass [2]. Chan and associates also showed that among 22 pediatric patients aged 1 15 years, plasma concentrations of hemostatic proteins decreased by an average of 56% immediately after the initiation of bypass [13]. Our findings support this as at the end of bypass, both the FFP and no FFP patients had fibrinogen levels and platelet counts well below their preoperative values. However the use of FFP in the prime did significantly offset the decrease in fibrinogen levels at the end of bypass. Bleeding and transfusion requirements remain important issues in pediatric patients undergoing cardiopulmonary bypass. Neonates and infants have been shown to be at particularly high risk for exposure to blood products after bypass [2 4, 6, 14]. Miller and associates reported that children weighing less that 8 kg have more severe coagulopathy, bleed more, and require more coagulation product transfusion than children weighing more than 8 kg [6]. Williams and associates found that both postoperative blood loss and blood product transfusion were higher in younger patients; among 414 consecutive children undergoing open heart procedures, the median number of blood products received was 2 U in children 1 5 years old, 6 U in children 1 12 months old, and8uinchildren less than 1 month old [4]. A subsequent prospective multivariate analysis by the same group showed that younger patient age was the most significant single risk factor for bleeding and transfusions in children undergoing open-heart surgery [5]. Chambers and associates reported that infants undergoing primary operations received a mean of 2.1 donor unit exposures for routine procedures and 6.1 exposures for complex procedures [15]. Our findings are in agreement
4 986 MCCALL ET AL Ann Thorac Surg FRESH FROZEN PLASMA IN THE PEDIATRIC PUMP PRIME 2004;77:983 7 with these studies: the mean total donor exposure in our study group was 4.8 U/patient. Decreasing the need for blood product transfusion in children after bypass is a desirable goal. The potential risks of blood product transfusion include transfusion reactions, immunosuppression, and transfusionassociated infection [16, 17]. Administration of blood products to a child after cardiopulmonary bypass carries additional risks: rapid infusion can cause volume overload, whereas inadequate infusion can result in ongoing bleeding. Postbypass correction of dilutional coagulopathy also entails the cost of the blood products as well as the cost of operating room time if chest closure is delayed. On average the patients in our FFP group received 1.3 fewer donor exposures per patient than the no FFP patients, a difference which approached statistical significance. The FFP patients tended to receive fewer packed red blood cell transfusions (1.8 versus 2.1 U/patient). However this may reflect the slightly higher preoperative mean hematocrit in the FFP patients as the two groups had no difference in mean hematocrit at ICU arrival or in 24-hour chest tube drainage. The lower donor exposure of the FFP group was primarily due to significantly fewer transfusions of cryoprecipitate (0.4 versus 2 U/patient). This was a direct result of the FFP group s higher mean fibrinogen level at the end of bypass along with the study protocol for cryoprecipitate transfusion. This protocol was designed before the study to provide a systematic approach to transfusion rather than relying solely on the discretion of the surgeon and anesthesiologist. The specific guidelines selected for transfusion of cryoprecipitate and platelets were selected because the fibrinogen level and platelet count at the end of bypass have been shown to be predictive of chest tube drainage over the first 24 hours in children weighing less than 8 kg [6]. The transfusion protocol is also in line with recommendations in the literature [1, 12, 16]. Another recent study examined the effects of FFP versus 5% albumin in the pump prime for pediatric cardiopulmonary bypass [7]. As in our study there was no difference in blood loss between the two groups although a subgroup analysis suggested that the use of FFP decreased blood loss in cyanotic patients and those having complex operations. In contrast to our results the FFP group had a greater total transfusion requirement although once adjustment was made for cyanotic patients there was no significant difference between the two groups [7]. The differing results of these two studies may be due to different approaches concerning the use of cryoprecipitate, which was used infrequently in their study and fibrin glue, which was used more frequently in their FFP group but not in any of our patients. Administration of FFP to pediatric patients after bypass, rather than in the pump prime, has been reported to be detrimental being associated with worsened coagulation parameters, greater chest tube drainage, and more coagulation product transfusion in the intensive care unit [6]. Both the current study and that of Oliver and associates [7] found that FFP could be added to the pump prime without compromising coagulation parameters or bleeding. It is possible that adding FFP to the pump before bypass may be more efficient than administering it after bypass-induced dilution has already occurred. Another approach to coagulation management in children undergoing cardiopulmonary bypass is the use of fresh whole blood. Manno and associates prospectively compared the relative effects of whole blood to those of blood reconstituted from packed red blood cells, platelets, and fresh frozen plasma [3]. Either whole blood or reconstituted blood was used both in the pump prime and for postbypass transfusion. They found that whole blood was more effective in decreasing postoperative bleeding in patients less than 2 years old undergoing complex operations. Whether the whole blood was less than 6 hours old or hours old did not make a significant difference. The authors suggested that improved platelet function accounted for the salutary effects of whole blood. They also pointed out that the platelets in the hour old blood presumably had decreased function due to storage at 4 C for at least 24 hours [3]. Further studies of the effects of fresh whole blood in pediatric open-heart surgery would help to clarify its role. Currently not all institutions have fresh whole blood routinely available. The use of FFP in the pump prime may provide a useful alternative. A limitation of this study was the small number of patients that did not allow delineation of any potential differences between cyanotic and acyanotic patients or those undergoing simple versus complex operations. Another limitation was the use of a transfusion protocol for cryoprecipitate and platelets. This directly affected the number of donor exposures in many of the study patients. In summary this prospective randomized study examined the inclusion of FFP in the pump prime of infants weighing less than 8 kg. Our findings suggest that the use of FFP may limit dilutional hypofibrinogenemia and decrease the need for postbypass transfusion of blood products. Further study is warranted in a larger number of patients, particularly cyanotic patients undergoing complex operations. The authors would like to thank Martha R. Stroud, MS, for statistical assistance. References 1. Guay J, Rivard G. Mediastinal bleeding after cardiopulmonary bypass in pediatric patients. Ann Thorac Surg 1996;62: Kern FH, Morana NJ, Sears JJ, Hickey PR. Coagulation defects in neonates during cardiopulmonary bypass. Ann Thorac Surg 1992;54: Manno CS, Hedberg KW, Kim HC, Bunjin GR, Nicolson S, Jobes D, Schwartz E, Norwood WI. Comparison of the hemostatic effects of fresh whole blood, stored whole blood, and components after open heart surgery in children. Blood 1991;77: Williams GD, Bratton SL, Riley EC, Ramamoorthy C. Asso-
5 Ann Thorac Surg MCCALL ET AL 2004;77:983 7 FRESH FROZEN PLASMA IN THE PEDIATRIC PUMP PRIME ciation between age and blood loss in children undergoing open heart operations. Ann Thorac Surg 1998;66: Williams GD, Bratton SL, Ramamoorthy C. Factors associated with blood loss and blood product transfusions: a multivariate analysis in children after open-heart surgery. Anesth Analg 1999;89: Miller BE, Mochizuki T, Levy JH, Bailey JM, Tosone SR, Tam VK, Kanter KR. Predicting and treating coagulopathies after cardiopulmonary bypass in children. Anesth Analg 1997;85: Oliver WC, Beynen FM, Nuttall GA, Schroeder DR, Ereth MH, Dearani JA, Puga FJ. Blood loss in infants and children for open heart operations: albumin 5% versus fresh-frozen plasma in the prime. Ann Thorac Surg 2003;75: Carrel TP, Schwanda M, Vogt PR, Turina MI. Aprotinin in pediatric cardiac operations: a benefit in complex malformations and with high-dose regimen only. Ann Thorac Surg 1998;66: Jaquiss RDB, Ghanayem NS, Zacharisen MC, Mussatto KA, Tweddell JS, Litwin SB. Safety of aprotinin use and re-use in pediatric cardiothoracic surgery. Circulation 2002;106(suppl I):I Tweddell JS, Hoffman GM, Mussatto KA, Fedderly RT, Berger S, Jaquiss RDB, Ghanayem NS, Frisbee SJ, Litwin SB. 987 Improved survival of patients undergoing palliation of hypoplastic left heart syndrome: lessons learned from 115 consecutive patients. Circulation 2002;106(suppl I):I Pouard P. Review of efficacy parameters. Ann Thorac Surg 1998;65:S Rinder CS. Hematologic effects of cardiopulmonary bypass. In: Gravlee GP, Davis RF, Kurusz M, Utley JR, eds. Cardiopulmonary bypass. Lippincott, Williams, & Wilkins: Philadelphia, PA, 2000: Chan AKC, Leaker M, Burrows FA, Williams WG, Gruenwald CE, Whyte L, et al. Coagulation and fibrinolytic profile of paediatric patients undergoing cardiopulmonary bypass. Thromb Haemostasis 1997;77: Petaja J, Lundstrom U, Lleijala M, Peltola K, Siimes MA. Bleeding and use of blood products after heart operations in infants. J Thorac Cardiovasc Surg 1995;109: Chambers LA, Cohen DM, Davis JT. Transfusion patterns in pediatric open-heart surgery. Transfusion 1996;36: Barcelona SL, Cote CJ. Pediatric resuscitation in the operating room. Anesth Clin North Am 2001;19: American Society of Anesthesiologists Task Force on Blood Component Therapy. Practice guidelines for blood component therapy. Anesthesiology 1996;84: DISCUSSION DR JAMES A. QUINTESSENZA (St. Petersburg, FL): I think it is a good idea to put FFP in the pump. The question I have is at what point in time do you put the FFP in? Is it at the beginning of the pump run or as you are rewarming right before you are going to come off and try to reverse your anticoagulants? DR MCCALL: In order to avoid the initial dilution, we put it in up front before we go on bypass. DR LYNN H. HARRISON (New Orleans, LA): Could you tell us a little bit about your modified ultrafiltration techniques and whether you go for a specified period of time or to a set volume, and was there any significant difference in the free water eluted by those techniques? DR MCCALL: There wasn t any difference in the amount of volume that we took off, and we standardized the amount of time that we MUF at 12 minutes, so all patients received the ultrafiltration for 12 minutes. We all used the same amount of vacuum on the suction, so similar volume amounts were removed. We pull blood from the aorta and reinfuse back through the venous side.
Blood Transfusion and Heart Surgery at Alder Hey. Philip Arnold, Consultant Paediatric Cardiac Anaesthetist, Alder Hey Children s Hospital, Liverpool
Blood Transfusion and Heart Surgery at Alder Hey Philip Arnold, Consultant Paediatric Cardiac Anaesthetist, Alder Hey Children s Hospital, Liverpool Blood and Hearts Transfusion has always been a feature
More informationComparison of Tranexamic Acid and Aminocaproic Acid in Coronary Bypass Surgery
Butler Journal of Undergraduate Research Volume 2 Article 24 2016 Comparison of Tranexamic Acid and Aminocaproic Acid in Coronary Bypass Surgery Lisa K. LeCleir Butler University, lisa.lecleir@gmail.com
More informationThe increasing use of normothermic cardiopulmonary
A Prospective, Randomized Study of Cardiopulmonary Bypass Temperature and Blood Transfusion Paul E. Stensrud, MD, Gregory A. Nuttall, MD, Maria A. de Castro, MD, Martin D. Abel, MD, Mark H. Ereth, MD,
More informationBLEEDING AND USE OF BLOOD PRODUCTS AFTER HEART OPERATIONS IN INFANTS
BLEEDING AND USE OF BLOOD PRODUCTS AFTER HEART OPERATIONS IN INFANTS From Children's Hospital, University of Helsinki, Finland. Received for publication March 10, 1994. Accepted for publication July 29,
More informationTRANSFUSION GUIDELINES FOR CARDIOTHORACIC UNIT 2006
TRANSFUSION GUIDELINES FOR CARDIOTHORACIC UNIT 2006 CTU blood product transfusion guidelines 2006 1 Summary of guidelines RED CELLS (10-15ml/kg) This applies to ward patients / icu patients who are stable.
More informationCCAS CPB Workshop Curriculum Outline Perfusion: What you might not know
CCAS CPB Workshop Curriculum Outline Perfusion: What you might not know Scott Lawson, CCP Carrie Striker, CCP Disclosure: Nothing to disclose Objectives: * Demonstrate how the cardiopulmonary bypass machine
More informationAlternative Anticoagulation during Cardiovascular Procedures in Pediatric Patients with Heparin-Induced Thrombocytopenia
The Journal of ExtraCorporeal Technology Alternative Anticoagulation during Cardiovascular Procedures in Pediatric Patients with Heparin-Induced Thrombocytopenia I. Ricardo Argueta-Morales, MD; Monica
More informationMajor Infection After Pediatric Cardiac Surgery: External Validation of Risk Estimation Model
Major Infection After Pediatric Cardiac Surgery: External Validation of Risk Estimation Model Andrzej Kansy, MD, PhD, Jeffrey P. Jacobs, MD, PhD, Andrzej Pastuszko, MD, PhD, Małgorzata Mirkowicz-Małek,
More informationIncreased postoperative blood loss after cardiac operations
Efficacy of Aprotinin, Epsilon Aminocaproic Acid, or Combination in Cyanotic Heart Disease Sandeep Chauhan, MD, Bisoi Akshay Kumar, MCh, Beeraka Heramba Rao, MD, Marigaddi Sanjeeva Rao, MCh, Bharat Dubey,
More informationGUIDELINES FOR THE TRANSFUSION OF BLOOD COMPONENTS
CHILDREN S HOSPITALS AND CLINICS OF MINNESOTA Introduction: GUIDELINES FOR THE TRANSFUSION OF BLOOD COMPONENTS These guidelines have been developed in conjunction with the hospital Transfusion Committee.
More informationGoing on Bypass. What happens before, during and after CPB. Perfusion Dept. Royal Children s Hospital Melbourne, Australia
Going on Bypass What happens before, during and after CPB. Perfusion Dept. Royal Children s Hospital Melbourne, Australia Circulation Brain Liver Kidneys Viscera Muscle Skin IVC, SVC Pump Lungs R.A. L.V.
More informationPerioperative Management of DORV Case
Perioperative Management of DORV Case James P. Spaeth, MD Department of Anesthesia Cincinnati Children s Hospital Medical Center University of Cincinnati Objectives: 1. Discuss considerations regarding
More informationBleeding, Coagulopathy, and Thrombosis in the Injured Patient
Bleeding, Coagulopathy, and Thrombosis in the Injured Patient June 7, 2008 Kristan Staudenmayer, MD Trauma Fellow UCSF/SFGH Trauma deaths Sauaia A, et al. J Trauma. Feb 1995;38(2):185 Coagulopathy is Multi-factorial
More informationThe incidence and risk factors of arrhythmias in the early period after cardiac surgery in pediatric patients
The Turkish Journal of Pediatrics 2008; 50: 549-553 Original The incidence and risk factors of arrhythmias in the early period after cardiac surgery in pediatric patients Selman Vefa Yıldırım 1, Kürşad
More informationIntraoperative haemorrhage and haemostasis. Dr. med. Christian Quadri Capoclinica Anestesia, ORL
Intraoperative haemorrhage and haemostasis Dr. med. Christian Quadri Capoclinica Anestesia, ORL Haemostasis is like love. Everybody talks about it, nobody understands it. JH Levy 2000 Intraoperative Haemorrhage
More information10/10/2018. Whole Blood vs. Component Prime Therapy in Neonatal & Pediatric CPB. Disclosure. Objectives. Historical Perspective
Disclosure Whole Blood vs. Component Prime Therapy in Neonatal & Pediatric CPB Thomas M. Klein, BS, CCP, FPP Department of Cardiovascular Perfusion Division of Cardiothoracic Surgery Cincinnati Children
More informationCABG in the Post-Aprotinin Era: Are We Doing Better? Ziv Beckerman, David Kadosh, Zvi Peled, Keren Bitton-Worms, Oved Cohen and Gil Bolotin
CABG in the Post-Aprotinin Era: Are We Doing Better? Ziv Beckerman, David Kadosh, Zvi Peled, Keren Bitton-Worms, Oved Cohen and Gil Bolotin DISCLOSURES None Objective(s): Our department routinely used
More informationHow can ROTEM testing help you in cardiac surgery?
How can ROTEM testing help you in cardiac surgery? Complicated bleeding situations can appear intra and post operatively. They can be life-threatening and always require immediate action. A fast differential
More informationThromboelastograph (TEG ) Utilization in Blood Management. Tim Shrewsberry, BS, CCP Firelands Regional Medical Center, Sandusky, OH
Thromboelastograph (TEG ) Utilization in Blood Management Tim Shrewsberry, BS, CCP Firelands Regional Medical Center, Sandusky, OH TEG Hemostasis System ROTEM Delta Whole blood Hemostasis Analyzer Personalized
More informationCardiopulmonary Bypass in Cyanotic Patients. A Review of the Problems and Suggested Strategies
Cardiopulmonary Bypass in Cyanotic Patients A Review of the Problems and Suggested Strategies Extra-ordinary Problems Encountered During C.P.B. for Cyanotic Heart Disease 1. Extra Dilutional Requirements
More informationBlood Management of the Cardiac Patient in the Postoperative Period
Blood Management of the Cardiac Patient in the Postoperative Period Al Stammers, MSA, CCP, Eric Tesdahl, PhD Andy Stasko MS, CCP, RRT, Linda Mongero, BS, CCP, Sam Weinstein, MD, MBA Goal To examine the
More informationTransfusion and Blood Conservation
Transfusion and Blood Conservation Kenneth G. Shann, CCP Assistant Director, Perfusion Services Senior Advisor, Performance Improvement Department of Cardiovascular and Thoracic Surgery Montefiore Medical
More informationIntroduction. Study Design. Background. Operative Procedure-I
Risk Factors for Mortality After the Norwood Procedure Using Right Ventricle to Pulmonary Artery Shunt Ann Thorac Surg 2009;87:178 86 86 Addressor: R1 胡祐寧 2009/3/4 AM7:30 SICU 討論室 Introduction Hypoplastic
More informationECMO vs. CPB for Intraoperative Support: How do you Choose?
ECMO vs. CPB for Intraoperative Support: How do you Choose? Shaf Keshavjee MD MSc FRCSC FACS Director, Toronto Lung Transplant Program Surgeon-in-Chief, University Health Network James Wallace McCutcheon
More informationCardiopulmonary bypass (CPB) is associated with an
SURGERY FOR CONGENITAL HEART DISEASE PULMONARY FUNCTION AFTER MODIFIED VENOVENOUS ULTRAFILTRATION IN INFANTS: A PROSPECTIVE, RANDOMIZED TRIAL Heather T. Keenan, MDCM, MPH a Ravi Thiagarajan, MBBS b Kenton
More informationRisk Factor Evaluation for Thrombosis and Bleeding in Pediatric Patients with Heart Disease
Risk Factor Evaluation for Thrombosis and Bleeding in Pediatric Patients with Heart Disease Kristen Nelson, MD Johns Hopkins University Director, Pediatric Cardiac Critical Care Why Does it Matter? Pediatric
More informationMASSIVE TRANSFUSION DR.K.HITESH KUMAR FINAL YEAR PG DEPT. OF TRANSFUSION MEDICINE
MASSIVE TRANSFUSION DR.K.HITESH KUMAR FINAL YEAR PG DEPT. OF TRANSFUSION MEDICINE CONTENTS Definition Indications Transfusion trigger Massive transfusion protocol Complications DEFINITION Massive transfusion:
More informationEast and Central African Journal of Surgery Volume 12 Number 2 November /December 2007
23 Modified Blalock-Taussig Shunt in Palliative Cardiac Surgery E.V. Ussiri 1, E.T.M. Nyawawa 1, U. Mpoki 2, E.R. Lugazia 2, G.C. Mannam 3, L.R. Sajja 4. S. Sompali 4 1 Specialist Surgeon, Cardiothoracic
More informationDo Heparinase Thrombelastographs Predict Postoperative Bleeding?
Original Article Do Heparinase Thrombelastographs Predict Postoperative Bleeding? Paulla Mashburn BS, Jodie Ecklund BS, CCP, Jeffrey Riley BA, CCT, CCP Program in Extracorporeal Circulation Technology,
More informationCardiopulmonary Support and Physiology
CSP Hemodilution and surgical hemostasis contribute significantly to transfusion requirements in patients undergoing coronary artery bypass Sandra Dial, MD, MSc, Eugene Delabays, MD, Martin Albert, MD,
More informationChildren with Single Ventricle Physiology: The Possibilities
Children with Single Ventricle Physiology: The Possibilities William I. Douglas, M.D. Pediatric Cardiovascular Surgery Children s Memorial Hermann Hospital The University of Texas Health Science Center
More informationEffective Date: Approved by: Laboratory Director, Jerry Barker (electronic signature)
1 of 5 Policy #: 702 (PHL-702-05) Effective Date: 9/30/2004 Reviewed Date: 8/1/2016 Subject: TRANSFUSION GUIDELINES Approved by: Laboratory Director, Jerry Barker (electronic signature) Approved by: Laboratory
More informationNavigating the Dichotomies Between Literature and Your Clinical Practice
Navigating the Dichotomies Between Literature and Your Clinical Practice Robert Groom, CCP, FPP Cardiovascular Institute at Maine Medical Center Disclosures No relevant conflicts related to this presentation
More informationRecombinant Factor Seven Therapy for Postoperative Bleeding in Neonatal and Pediatric Cardiac Surgery
Recombinant Factor Seven Therapy for Postoperative Bleeding in Neonatal and Pediatric Cardiac Surgery Hemant S. Agarwal, MBBS, Jo E. Bennett, BS, Kevin B. Churchwell, FAAP, MD, Karla G. Christian, MD,
More informationThromboelastography Use in the Perioperative Transfusion Management of a Patient with Hemophilia A Undergoing Liver Transplantation
Open Journal of Organ Transplant Surgery, 2013, 3, 13-17 http://dx.doi.org/10.4236/ojots.2013.31003 Published Online February 2013 (http://www.scirp.org/journal/ojots) Thromboelastography Use in the Perioperative
More informationIs the patient at risk for blood loss of 1000 mls? Avoid these Guidelines. Avoid these Guidelines. Yes. Yes. Yes. Yes. Yes
Clinical Guidelines Acute rmovolemic Hemodilution Guidelines for Cardiac Surgery Department of Anesthesiology and Perioperative Medicine Date: 12-30-2012 Is the patient at risk for blood loss of 1000 mls?
More informationMassive transfusion: Recent advances, guidelines & strategies. Dr.A.Surekha Devi Head, Dept. of Transfusion Medicine Global Hospital Hyderabad
Massive transfusion: Recent advances, guidelines & strategies Dr.A.Surekha Devi Head, Dept. of Transfusion Medicine Global Hospital Hyderabad Massive Hemorrhage Introduction Hemorrhage is a major cause
More informationAdult Congenital Heart Disease: The New Reality. Disclosures
Adult Congenital Heart Disease: The New Reality Kathryn Rouine-Rapp, MD Professor of Anesthesia Disclosures I have nothing to disclose 1 Outline Historic perspective Our reality Common lesions Guidelines
More informationTEG-Directed Transfusion in Complex Cardiac Surgery: Impact on Blood Product Usage
TEG-Directed Transfusion in Complex Cardiac Surgery: Impact on Blood Product Usage Kevin Fleming, CCP; Roberta E. Redfern, PhD; Rebekah L. March, MPH; Nathan Bobulski, CCP; Michael Kuehne, PhD, PA-C; John
More informationIncidence and treatment of chylothorax after cardiac surgery in children: analysis of a large multi-institutional database. Carlos M.
Incidence and treatment of chylothorax after cardiac surgery in children: analysis of a large multi-institutional database Carlos M. Mery, MD, MPH Assistant Professor, and Pediatrics Congenital Heart Texas
More informationReplacement of aprotinin by 1-aminocaproic acid in infants undergoing cardiac surgery: consequences for blood loss and outcome
British Journal of Anaesthesia 110 (4): 615 21 (2013) Advance Access publication 4 December 2012. doi:10.1093/bja/aes430 Replacement of aprotinin by 1-aminocaproic acid in infants undergoing cardiac surgery:
More informationFactors affecting postoperative blood loss in children undergoing cardiac surgery
Faraoni and Van der Linden Journal of Cardiothoracic Surgery 2014, 9:32 LETTER TO THE EDITOR Factors affecting postoperative blood loss in children undergoing cardiac surgery David Faraoni * and Philippe
More informationOriginal Article: Janak Mehta Award. Introduction. Vandana Bhardwaj, Poonam Malhotra, Suruchi Hasija, Ujjwal Kumar Chowdury 1, Neha Pangasa
Original Article: Janak Mehta Award Coagulopathies in Cyanotic Cardiac Patients: An Analysis with Three Point of care Testing Devices (Thromboelastography, Rotational Thromboelastometry, and Sonoclot Analyzer)
More informationComparing Two Strategies of Cardiopulmonary Bypass Cooling on Jugular Venous Oxygen Saturation in Neonates and Infants
Comparing Two Strategies of Cardiopulmonary Bypass Cooling on Jugular Venous Oxygen Saturation in Neonates and Infants Frank H. Kern, MD, Ross M. Ungerleider, MD, Scott R. Schulman, MD, Jon N. Meliones,
More informationIntraoperative Autologous Blood Donation Preserves Red Cell Mass But Does Not Decrease Postoperative Bleeding
Intraoperative Autologous Blood Donation Preserves Red Cell Mass But Does Not Decrease Postoperative Bleeding Robert E. Helm, MD, John D. Klemperer, MD, Todd K. Rosengart, MD, Jeffrey P. Gold, MD, Powers
More informationInadequate anticoagulation with heparin in the setting
Individualized Heparin and Protamine Management in Infants and Children Undergoing Cardiac Operations Massimiliano Codispoti, MD, Christopher A. Ludlam, PhD, David Simpson, FRCA, and Pankaj S. Mankad,
More informationGuidelines for Anticoagulation in Paediatric Cardiac Patients
Leeds Children s Hospital Guidelines for Anticoagulation in Paediatric Cardiac Patients SURGICAL PATIENTS Preoperative Management Blalock-Taussig (BT) Shunt / Fontan circulation / Sano Shunt and Severe
More informationBlood Transfusion Guidelines in Clinical Practice
Blood Transfusion Guidelines in Clinical Practice Salwa Hindawi Director of Blood Transfusion Services Associate Professor in Haematology and Transfusion Medicine King Abdalaziz University, Jeddah Saudi
More informationThe Treatment of Postperfusion Bleeding Using wlminocaproic Acid, Cryoprecipitate, Fresh-Frozen Plasma, and Protamine Sulfate
The Treatment of Postperfusion Bleeding Using wlminocaproic Acid, Cryoprecipitate, Fresh-Frozen Plasma, and Protamine Sulfate Cary J. Lambert, M.D., Alain J. Marengo-Rowe, M.D., James E. Leveson, Ph.D.,
More information2012, Görlinger Klaus
Gerinnungsmanagement der Gegenwart - wie gehen wir heute vor? 25. Allander Gerinnungsrunde am 15. März 2012 Klaus Görlinger Universitätsklinikum Essen klaus@goerlinger.net CSL Behring GmbH Octapharma AG
More informationMid-term Result of One and One Half Ventricular Repair in a Patient with Pulmonary Atresia and Intact Ventricular Septum
Mid-term Result of One and One Half Ventricular Repair in a Patient with Pulmonary Atresia and Intact Ventricular Septum Kagami MIYAJI, MD, Akira FURUSE, MD, Toshiya OHTSUKA, MD, and Motoaki KAWAUCHI,
More informationAprotinin is a serine protease inhibitor that was first used
Safety of Aprotinin Use and Re-Use in Pediatric Cardiothoracic Surgery Robert D.B. Jaquiss, MD; Nancy S. Ghanayem, MD; Michael C. Zacharisen, MD; Kathleen A. Mussatto, RN, BSN; James S. Tweddell, MD; S.
More informationCardiac anaesthesia. Simon May
Cardiac anaesthesia Simon May Contents Cardiac: Principles of peri-operative management for cardiac surgery Cardiopulmonary bypass, cardioplegia and off pump cardiac surgery Cardiac disease and its implications
More informationCardiac surgery is associated with a high incidence of
Retrograde Autologous Priming of the Cardiopulmonary Bypass Circuit Reduces Blood Transfusion After Coronary Artery Surgery Subramaniam Balachandran, FRCA, Michael H. Cross, FRCA, Sivagnanam Karthikeyan,
More informationDoes troponin-i measurement predict low cardiac output syndrome following cardiac surgery in children?
Does troponin-i measurement predict low cardiac output syndrome following cardiac surgery in children? Norbert R Froese, Suvro S Sett, Thomas Mock and Gordon E Krahn Low cardiac output syndrome (LCOS)
More informationDetection of coagulopathy in paediatric heart surgery [DECISION study]: study protocol
Underwood et al. BMC Hematology (2015) 15:11 DOI 10.1186/s12878-015-0030-8 STUDY PROTOCOL Detection of coagulopathy in paediatric heart surgery [DECISION study]: study protocol Open Access Wendy Underwood
More informationC CONFERENCIAS MAGISTRALES Vol. 36. Supl. 1 Abril-Junio 2013 pp S31-S35 Bleeding following deep hypothermia and circulatory arrest in children Emad B Mossad, MD* * Division of Pediatric Cardiovascular
More informationFirst-stage palliation for hypoplastic left heart syndrome
Comparison of Norwood Shunt Types: Do the Outcomes Differ 6 Years Later? Eric M. Graham, MD, Sinai C. Zyblewski, MD, Jacob W. Phillips, MD, Girish S. Shirali, MBBS, Scott M. Bradley, MD, Geoffery A. Forbus,
More informationCoagulopathy: Measuring and Management. Nina A. Guzzetta, M.D. Children s Healthcare of Atlanta Emory University School of Medicine
Coagulopathy: Measuring and Management Nina A. Guzzetta, M.D. Children s Healthcare of Atlanta Emory University School of Medicine No Financial Disclosures Objectives Define coagulopathy of trauma Define
More informationSurvival Rates of Children with Congenital Heart Disease continue to improve.
DOROTHY RADFORD Survival Rates of Children with Congenital Heart Disease continue to improve. 1940-20% 1960-40% 1980-70% 2010->90% Percentage of children with CHD reaching age of 18 years 1938 First Patent
More informationIntra-operative Effects of Cardiac Surgery Influence on Post-operative care. Richard A Perryman
Intra-operative Effects of Cardiac Surgery Influence on Post-operative care Richard A Perryman Intra-operative Effects of Cardiac Surgery Cardiopulmonary Bypass Hypothermia Cannulation events Myocardial
More informationCYANOTIC CONGENITAL HEART DISEASES. PRESENTER: DR. Myra M. Koech Pediatric cardiologist MTRH/MU
CYANOTIC CONGENITAL HEART DISEASES PRESENTER: DR. Myra M. Koech Pediatric cardiologist MTRH/MU DEFINITION Congenital heart diseases are defined as structural and functional problems of the heart that are
More informationAdvances in Transfusion and Blood Conservation
Advances in Transfusion and Blood Conservation Arman Kilic, MD Division of Cardiac Surgery, Department of Surgery, Johns Hopkins Hospital, Baltimore, MD No relevant financial relationships to disclose.
More informationMANAGEMENT OF OVERANTICOAGULATION AND PREOPERATIVE MANAGEMENT OF WARFARIN DOSE 1. GUIDELINES FOR THE MANAGEMENT OF AN ELEVATED INR
MANAGEMENT OF OVERANTICOAGULATION AND PREOPERATIVE MANAGEMENT OF WARFARIN DOSE 1. GUIDELINES FOR THE MANAGEMENT OF AN ELEVATED INR 1.1 Time to lower INR Prothrombinex-VF - 15 minutes Fresh Frozen Plasma
More informationPRACTICE guidelines are systematically developed recommendations that assist the
Embargoed for release until approved by ASA House of Delegates. No part of this document may be released, distributed or reprinted until approved. Any unauthorized copying, reproduction, appropriation
More informationCongenital heart disease: When to act and what to do?
Leading Article Congenital heart disease: When to act and what to do? Duminda Samarasinghe 1 Sri Lanka Journal of Child Health, 2010; 39: 39-43 (Key words: Congenital heart disease) Congenital heart disease
More informationRecent technical advances and increasing experience
Pediatric Open Heart Operations Without Diagnostic Cardiac Catheterization Jean-Pierre Pfammatter, MD, Pascal A. Berdat, MD, Thierry P. Carrel, MD, and Franco P. Stocker, MD Division of Pediatric Cardiology,
More informationHemostasis and thrombosis in patients with liver disease. Ton Lisman, Dept Surgery, UMC Groningen, The Netherlands
Hemostasis and thrombosis in patients with liver disease Ton Lisman, Dept Surgery, UMC Groningen, The Netherlands Importance of the liver in hemostasis Synthesis of Coagulation factors Fibrinolytic proteins
More informationPatients at Risk for Low Systemic Oxygen Delivery After the Norwood Procedure
Patients at Risk for Low Systemic Oxygen Delivery After the Norwood Procedure James S. Tweddell, MD, George M. Hoffman, MD, Raymond T. Fedderly, MD, Nancy S. Ghanayem, MD, John M. Kampine, MD, Stuart Berger,
More informationOperative Closure of Isolated Defects of the Ventricular Septum: Planned Delay
Operative Closure of Isolated Defects of the Ventricular Septum: Planned Delay R. Darryl Fisher, M.D., Scott L. Faulkner, M.D., C. Gordon Sell, M.D., Thomas P. Graham, Jr., M.D., and Harvey W. Bender,
More informationManagement of a Patient after the Bidirectional Glenn
Management of a Patient after the Bidirectional Glenn Melissa B. Jones MSN, APRN, CPNP-AC CICU Nurse Practitioner Children s National Health System Washington, DC No Disclosures Objectives qbriefly describe
More informationA Unique Milieu for Perioperative Care of Adult Congenital Heart Disease Patients at a Single Institution
Original Article A Unique Milieu for Perioperative Care of Adult Congenital Heart Disease Patients at a Single Institution Ghassan Baslaim, MD, and Jill Bashore, RN Purpose: Adult patients with congenital
More informationTotal Anomalous Pulmonary Venous Connection: Factors Associated With Mortality and Recurrent Pulmonary Venous Obstruction
Total Anomalous Pulmonary Venous Connection: Factors Associated With Mortality and Recurrent Pulmonary Venous Obstruction S. Adil Husain, MD, Elaine Maldonado, MD, Debbie Rasch, MD, Joel Michalek, MD,
More informationManagement of the changeover of inotrope infusions in children
Intensive and Critical Care Nursing (2004) 20, 275 280 ORIGINAL ARTICLE Management of the changeover of inotrope infusions in children Melanie Arino a, Jane P. Barrington a, Anne L. Morrison a,, Donna
More informationCerebral near-infrared spectroscopy during cardiopulmonary bypass predicts superior vena cava oxygen saturation
Cerebral near-infrared spectroscopy during cardiopulmonary bypass predicts superior vena cava oxygen saturation Richard Ginther, CCP, a Vinod A. Sebastian, MD, b Rong Huang, MS, c Steven R. Leonard, MD,
More informationDIAGNOSIS, MANAGEMENT AND OUTCOME OF HEART DISEASE IN SUDANESE PATIENTS
434 E AST AFRICAN MEDICAL JOURNAL September 2007 East African Medical Journal Vol. 84 No. 9 September 2007 DIAGNOSIS, MANAGEMENT AND OUTCOME OF CONGENITAL HEART DISEASE IN SUDANESE PATIENTS K.M.A. Sulafa,
More informationcan be attributed to improvements in diagnostic
Cardiac Intensive Care Early postoperative outcomes in a series of infants with hypoplastic left heart syndrome undergoing stage I palliation operation with either modified Blalock-Taussig shunt or right
More informationGuidelines for Use of Canine Blood Components
Guidelines for Use of Canine Blood Components Cryoprecipitate This product is prepared by a controlled thaw of fresh frozen plasma, resulting in a concentration of Factor VIII, Factor XIII, vwf and some
More informationJournal of the American College of Cardiology Vol. 33, No. 6, by the American College of Cardiology ISSN /99/$20.
Journal of the American College of Cardiology Vol. 33, No. 6, 1999 1999 by the American College of Cardiology ISSN 0735-1097/99/$20.00 Published by Elsevier Science Inc. PII S0735-1097(99)00061-3 for Prediction
More informationCase scenario V AV ECMO. Dr Pranay Oza
Case scenario V AV ECMO Dr Pranay Oza Case Summary 53 y/m, k/c/o MVP with myxomatous mitral valve with severe Mitral regurgitation underwent Mitral valve replacement with mini thoracotomy Pump time nearly
More informationADULT TRANSFUSION GUIDELINES ORDERED COMPONENT
ADULT TRANSFUSIN GUIDELINES RDERED Packed red cells (RBCs) RBCs, WBCs, platelets & plasma (minimal) Increase red cell mass and oxygen carrying capacity; generally indicated when Hgb is 7 gm or Hct 21 unless
More informationSurgical Management of TOF in Adults. Dr Flora Tsang Associate Consultant Department of Cardiothoracic Surgery Queen Mary Hospital
Surgical Management of TOF in Adults Dr Flora Tsang Associate Consultant Department of Cardiothoracic Surgery Queen Mary Hospital Tetralogy of Fallot (TOF) in Adults Most common cyanotic congenital heart
More informationThe Journal of Thoracic and Cardiovascular Surgery c Volume 139, Number
The effectiveness of prestorage leukocyte-reduced red blood cell transfusion on perioperative inflammatory response with a miniaturized biocompatible bypass system Kagami Miyaji, MD, PhD, Takashi Miyamoto,
More informationPattern of Congenital Heart Disease A Hospital-Based Study *Sadiq Mohammed Al-Hamash MBChB, FICMS
Pattern of Congenital Heart Disease A Hospital-Based Study *Sadiq Mohammed Al-Hamash MBChB, FICMS ABSTRACT Background: The congenital heart disease occurs in 0,8% of live births and they have a wide spectrum
More informationWithin coronary patients, those who are affected by
The Role of Antithrombin III in the Perioperative Management of the Patient With Unstable Angina Marco Rossi, MD, Lorenzo Martinelli, MD, Sergio Storti, MD, Michele Corrado, MD, Roberto Marra, MD Carmelita
More informationAbsolute Cerebral Oximeters for Cardiovascular Surgical Cases
Absolute Cerebral Oximeters for Cardiovascular Surgical Cases Mary E. Arthur, MD, Associate Professor, Anesthesiology and Perioperative Medicine Medical College of Georgia at Georgia Regents University
More informationTechnique Article. Jeffrey B. Riley;* Gregory J. Schears; Gregory A. Nuttall; William C. Oliver, Jr.; Mark H. Ereth; Joseph A.
The Journal of ExtraCorporeal Technology Technique Article Coagulation Parameter Thresholds Associated with Non-Bleeding in the Eighth Hour of Adult Cardiac Surgical Post-Cardiotomy Extracorporeal Membrane
More informationEach year in the United States more than 20,000 infants
Recognition and Management of Heparin-Induced Thrombocytopenia in Pediatric Cardiopulmonary Bypass Patients Lynn K. Boshkov, MD, Aileen Kirby, MD, Irving Shen, MD, and Ross M. Ungerleider, MD Departments
More informationRecombinant Activated Factor VII: Useful. Department of Surgery Grand Rounds 11/8/10 David Mauchley MD
Recombinant Activated Factor VII: Useful Department of Surgery Grand Rounds 11/8/10 David Mauchley MD Hemostasis and Coagulation Traditional cascade model Two convergent pathways Series of proteolytic
More informationUnderstanding the Cardiopulmonary Bypass Machine and Its Tubing
Understanding the Cardiopulmonary Bypass Machine and Its Tubing Robert S. Leckie, MD Division of Cardiac Anesthesia, Beth Israel Deaconess Medical Center ABL 1/09 Reservoir Bucket This is a cartoon of
More informationInflow Occlusion for Semilunar Valve Stenosis
Inflow Occlusion for Semilunar Valve Stenosis Robert M. Sade, M.D., Fred A. Crawford, M.D., and Arno R. Hohn, M.D ABSTRACT Twenty-nine patients have had valvotomy with inflow occlusion since 1975 at our
More informationReliable indicators of morbidity and mortality after
CHANGES IN WHOLE BLOOD LACTATE LEVELS DURING CARDIOPULMONARY BYPASS FOR SURGERY FOR CONGENITAL CARDIAC DISEASE: AN EARLY INDICATOR OF MORBIDITY AND MORTALITY Ricardo Munoz, MD a Peter C. Laussen, MBBS
More informationRepair of Complete Atrioventricular Septal Defects Single Patch Technique
Repair of Complete Atrioventricular Septal Defects Single Patch Technique Fred A. Crawford, Jr., MD The first repair of a complete atrioventricular septal defect was performed in 1954 by Lillehei using
More informationThe evolution of the Fontan procedure for single ventricle
Hemi-Fontan Procedure Thomas L. Spray, MD The evolution of the Fontan procedure for single ventricle cardiac malformations has included the development of several surgical modifications that appear to
More informationA structured blood conservation program in pediatric cardiac surgery
European Review for Medical and Pharmacological Sciences 2017; 21: 1074-1079 A structured blood conservation program in pediatric cardiac surgery A.B. BUDAK 1, K. MCCUSKER 1, S. GUNAYDIN 2 1 Department
More informationQuantitative Evaluation of Hypothermia, Hyperthermia, and Hemodilution on Coagulation
The Journal of The American Society of ExtraCorporeal Technology Quantitative Evaluation of Hypothermia, Hyperthermia, and Hemodilution on Coagulation Scott A. Kmiecik, MPS; Jun-Li Liu, MPS, MD, PhD; Tal
More informationEDUCATIONAL COMMENTARY DISSEMINATED INTRAVASCULAR COAGULATION
EDUCATIONAL COMMENTARY DISSEMINATED INTRAVASCULAR COAGULATION Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain FREE CME/CMLE
More informationUniversity of Florida Department of Surgery. CardioThoracic Surgery VA Learning Objectives
University of Florida Department of Surgery CardioThoracic Surgery VA Learning Objectives This service performs coronary revascularization, valve replacement and lung cancer resections. There are 2 faculty
More informationHemorrhagic complications of cardiac surgery represent
Factor V Leiden Protects Against Blood Loss and Transfusion After Cardiac Surgery Brian S. Donahue, MD, PhD; David Gailani, MD; Michael S. Higgins, MD, MPH; Davis C. Drinkwater, MD; Alfred L. George, Jr,
More informationSURGICAL TREATMENT AND OUTCOME OF CONGENITAL HEART DISEASE
SURGICAL TREATMENT AND OUTCOME OF CONGENITAL HEART DISEASE Mr. W. Brawn Birmingham Children s Hospital. Aims of surgery The aim of surgery in congenital heart disease is to correct or palliate the heart
More information